UNSPSC 51434904: Aliskiren/valsartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434904 Aliskiran/valsartan is a Commodity code for a specific antihypertensive pharmaceutical combination product, though state and local government procurement activity under this code shows limited match to the product name itself. Recent opportunities tagged to this code reflect broader pharmaceutical supply rather than this specific drug formulation — the Tampa Fire Rescue advanced life support medications bid calls for epinephrine, labetalol, adenosine, and diltiazem, none of which are aliskiren/valsartan; the Texas HHS Commission RFI solicits vendor capabilities for a direct-to-manufacturer prescription program covering a wide pharmacy benefit portfolio; and the Minnesota MMCAP cooperative purchasing RFP establishes multi-vendor contracts for generic pharmaceuticals and OTC products across state and local health systems. The code appears to serve as a catch-all pharmaceutical classification rather than a line-item product identifier in state and local procurement systems, reflecting how these jurisdictions source medications through wholesalers and group purchasing organizations rather than by specific drug combinations.

Issuing bodies include municipal fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and local governments (Minnesota MMCAP, which includes Oregon participation). Geographic activity centers on Florida, Texas, and Minnesota with multistate cooperative extension. The Tampa Fire Rescue opportunity (Bid No. 26-P-00188, IFB, due April 8, 2026, estimated value $40,000) required sealed bids for four specific medication line items with nine-month minimum expiration, firm pricing including freight to Tampa, and one-year contract term with renewal options, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota MMCAP RFP (due March 26, 2026) established two-year pharmaceutical supply contracts effective July 1, 2026, requiring vendors to work through three authorized wholesalers and certify cGMP and Drug Supply Chain Security Act compliance, with pricing weighted at 75 percent of evaluation and administrative fees of 3 percent on all purchases. The Texas RFI (due April 3, 2026) explored direct-manufacturer prescription program capabilities without committed contract values, positioned as market intelligence to inform future formal RFP development.